Status: Not yet recruiting
An Extension Trial of Asedebart in Participants With Congenital Adrenal Hyperplasia
The main goal of the trial is to study the long-term safety, how well people can handle the treatment, and how asedebart acts in the body and affects the body when used to treat classic congenital adrenal hyperplasia (CAH). The trial will include participants who have previously received asedebart in trial 19873A (NCT05669950).
Participants needed: 45
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: H. Lundbeck A/SUpdated: Oct 5, 2026
Eligibility criteria
The participant has been treated with asedebart in a clinical trial. [+4]
The participant has known hypersensitivity or intolerance to asedebart or its ex... [+3]